Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893617 | 0.90 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL4891283 | 0.90 | PTGS2 (0.93) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL13575819 | 0.88 | PTGS2 (0.83) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL28319282 | 0.84 | PTGS2 (0.95) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29366203 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL14163961 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29402456 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL4680 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL30988052 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5210195 | 0.83 | PTGS2 (0.82) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858909-B2 | Deuterated etoricoxib, methods of manufacture, and use thereof | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858909-B2 | Deuterated etoricoxib, methods of manufacture, and use thereof | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11161833-B1 | Deuterated etoricoxib, methods of manufacture, and use thereof | Tremeau Pharmaceuticals, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161833-B1 | Deuterated etoricoxib, methods of manufacture, and use thereof | PTGES3, CYP3A43, PTGER3 | PTGS2 22/4885PTGS1 12/4885ABCC4 2205/4885 |
| US-11858909-B2 | Deuterated etoricoxib, methods of manufacture, and use thereof | PTGES3, CYP3A43, PTGER3 | PTGS2 22/4885PTGS1 12/4885ABCC4 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.